PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
34.37%
Some net income increase while CRVO is negative at -6863.43%. John Neff would see a short-term edge over the struggling competitor.
0.63%
Some D&A expansion while CRVO is negative at -0.02%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
-79.79%
Negative yoy SBC while CRVO is 0.00%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-121.40%
Negative yoy working capital usage while CRVO is 942.94%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-200.00%
Both negative yoy AP, with CRVO at -61.51%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-91.42%
Negative yoy usage while CRVO is 3773.40%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
2.52%
Lower 'other non-cash' growth vs. CRVO's 1111.49%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
-18.12%
Negative yoy CFO while CRVO is 77.94%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while CRVO is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.